Bristol Myers Squibb Opdivo nivolumab Plus Low-Dose Yervoy ipilimumab Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer
Durable Clinical Benefit With Nivolumab Plus Ipilimumab In Dna Mismatch Repair

Certainly, relevant therapeutic approaches await exploration in high-quality clinical trials. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Using a syngeneic colorectal cancer mouse model, our group previously demonstrated that TMZ treatment led to the emergence of MMRd cells among an otherwise MMRp cell population .

Why are ipilimumab and nivolumab used together?

When used together, nivolumab and ipilimumab can treat advanced melanoma more effectively than each drug on its own. This combination of two immunotherapy drugs can shrink tumors and help patients live longer.

Colorectal cancer is one of the most common and lethal cancers, representing around 10% of new cancer diagnoses and 9% of cancer-related deaths . Although the 5-year relative overall survival rate ranges between 68% and 90% in localized disease (stages I–III), the rate in stage IV metastatic colorectal cancer is still dismal, dropping to between 11% and 14% . Among patients who responded to the combination, 94% were still responding at the time of data cutoff, and at the time of this report, 63% of the nivolumab/ipilimumab cohort remained on treatment. These results are particularly striking considering 76% of these patients had received two or more prior lines of therapy, he added. When analyzed according to patient subsets, “responses were observed irrespective of tumor PD-1 expression,BRAForKRASmutational status, or clinical history of Lynch syndrome,” he said. The updated analysis followed patients to 21 months and in an exploratory analysis, assessed for efficacy by prior chemotherapy.

Immunotherapy combinations with tyrosine kinase inhibitors (TKIs) are anticipated to be scheduled in the future

Multiple prospective studies have been conducted worldwide to explore the efficacy of ICB with TKI therapy in the treatment of MSS mCRC. Patients treated with the combination experienced an objective response rate of 69% (95% CI, 53%-82%) and a disease control rate of 84% (95% CI, 70.5%-93.5%). The median duration of response was not reached, and 74% of patients had Durable Clinical Benefit With Nivolumab Plus Ipilimumab In Dna Mismatch Repair ongoing responses at the time of data cutoff. Additionally, after a minimum follow-up of 24.2 months, the median progression-free survival and overall survival were not reached. The primary study end point was PFS, which encompassed the time from first dose of pembrolizumab to first evidence of disease progression or death from any cause, whichever occurred first.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab In Dna Mismatch Repair

Eight patients (20%) experienced a grade 3 or 4 AE , which led to 2 (5%) discontinuing treatment due to toxic effects attributed to pembrolizumab. Treatment-related adverse effects occurring in at least 20% of patients included diarrhea, fatigue, pruritus, and arthralgia. Most TRAEs with potential immunologic origin including endocrine, gastrointestinal, hepatic, pulmonary, renal, and skin toxicities were grade 1 or 2. Responses were durable across cohorts, with a median duration of response that was not reached at data cutoff.

Nivolumab Plus Ipilimumab Displays Durable Benefit in MSI-H/dMMR mCRC

Combination regimens and/or the use of immunotherapy as a maintenance after induction non-immunologic systemic therapy may be the way forward to improve outcomes. The REGONIVO study in Japan was a phase Ib study using nivolumab plus regorafenib in refractory MSS CRC and gastric cancer. This study demonstrated an ORR of 28% and a mPFS of 7.8 months (95% CI, 2.8 to NR) in mCRC, with a 1-year PFS rate of 41.7% and a 1-year OS rate of 68.0%, which were considerably higher than the data from previous studies in MSS CRC . However, this study could not be repeated in the follow-up North American REGONIVO phase II study , and an ORR of 7.1%, mPFS of 8 weeks, and a mOS of 52 weeks were reported . The REGOTORI study indicated that 5 out of 33 evaluable patients treated with 80 mg regorafenib achieved a tumor response with an ORR of 15.2% (95% CI, 5.7%–32.7%) and a DCR of 36.4% (95% CI, 21.0% to 54.9). The ORR was higher in patients without liver metastasis than that noted in those with liver metastasis (30.0% vs. 8.7%).

  • We also continue to pioneer research that will help facilitate a deeper understanding of the role of immune biomarkers and how a patient’s tumor biology can be used as a guide for treatment decisions throughout their journey.
  • Additionally, after a minimum follow-up of 24.2 months, the median progression-free survival and overall survival were not reached.
  • The cosine was used to evaluate the similarity between the original mutational profile and the reconstructed mutational profile based on the optimal linear combination of all COSMIC signatures identified after fitting .
  • TMB analysis was also performed on samples from five patients with an available pre-TMZ tissue biopsy (Fig. 1).
  • Inhibition of angiogenesis has long been considered as a potential approach to reverse immunotherapy resistance.

Despite recent progress exploiting targeted therapies such as a combination of BRAF and EGFR inhibitors for BRAFV600E-mutant tumors or HER2 blockade in HER2-positive ones, treatment developments have been incremental rather than transformative (5–9). The median duration of response was still not reached in the overall cohort or in the two subgroups . Among responders, 80% had ongoing responses at the time of data cutoff, and 64% had responses lasting at least 1 year.

Tinggalkan Balasan

Alamat email Anda tidak akan dipublikasikan. Ruas yang wajib ditandai *